Effects of Yishenjiangzhuo granules on immunity and bone metabolism in patients with stage 3-4 chronic kidney disease

被引:0
|
作者
Jing Zheng [1 ]
Yingda Lin [2 ]
Lu Huang [3 ]
Caifeng Chen [3 ]
Xuemin Zheng [3 ]
Xinhong Wu [3 ]
Ciyun Liu [3 ]
机构
[1] Nephropathy Department, Fujian Provincial People's Hospital
[2] Teaching and Research Section of Internal Medicine, Fujian Provincial People's Hospital
[3] Postgraduate Department, Integration of Traditonal Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine
关键词
B lymphocytes; T-lymphocytes; regulatory; Osteocalcin; Acid phosphatase; Yishenjiangzhuo granules;
D O I
暂无
中图分类号
R692 [肾疾病];
学科分类号
摘要
OBJECTIVE:To determine the effects of Yishenjiangzhuo granules(YJG)on bone metabolism and to explore the changes in levels of bone Gla protein(BGP),tartrate-resistant acid phosphatase(TRAP),as well as their relationships with levels of B cells,regulatory T cells(Treg)and interleukin(IL)-17 in patients with stage 3-4 chronic kidney disease(CKD)before and after treatment.METHODS:Fifty-three stage 3-4 CKD patients were divided randomly into two groups:YJG treatment and control.Peripheral blood was taken from two groups of CKD patients and 21 healthy subjects in the normal group.The parameters determined were the levels of CD4+,CD19+,CD19+CD69+,CD19+AV,Treg(CD4+CD25+CD127lo),BGP,TRAP,IL-17,calcium,phosphate,blood urea nitrogen,serum creatinine(SCr),hemoglobin(Hb)in peripheral blood,and urinary creatinine.Calcium-phosphate products and endogenous creatinine clearance rate(CCr)were calculated according to standard protocols.RESULTS:In YJG and control groups,SCr levels were lowered(P<0.01)after treatment,whereas CCr(P<0.05)as well as Hb and albumin levels(P<0.01)were increased.The changes in levels of CCr and SCr in the YJG group were more significant.After treatment,CD19+CD69+and Treg levels in the two groups varied(P<0.01)compared with those of the normal group;the level of CD19+increased but the levels of CD4+and CD19+AV decreased(P<0.01)in both groups.Compared with the control group,the changes of CD19+and CD19+AV in the YJG group were more apparent(P<0.05).Compared with the normal group,levels of IL-17 in both groups increased significantly(P<0.01),and the difference in the control group was more significant(P<0.05).After treatment,the TRAP level increased(P<0.05),but the difference in BGP level(P>0.05)was not significant.CONCLUSION:In stage 3-4 CKD patients,B cells and IL-17 participated in the induction of osteoclast activation.YJG could also elevate the level of B cells and decrease their apoptosis,but showed no significant effects on active B cells,IL-17 or osteoclast activity.
引用
收藏
页码:620 / 625
页数:6
相关论文
共 50 条
  • [21] Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease
    Coyne, Daniel W.
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2008, 4 (07): : 364 - 365
  • [22] Progression of kidney disease in elderly stage 3 and 4 chronic kidney disease patients
    Pradeep Arora
    Kabir Jalal
    Anu Gupta
    Randolph L. Carter
    James W. Lohr
    International Urology and Nephrology, 2017, 49 : 1033 - 1040
  • [23] Progression of kidney disease in elderly stage 3 and 4 chronic kidney disease patients
    Arora, Pradeep
    Jalal, Kabir
    Gupta, Anu
    Carter, Randolph L.
    Lohr, James W.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (06) : 1033 - 1040
  • [24] Pro: Should phosphate binders be used in chronic kidney disease stage 3-4? comments
    Kestenbaum, Bryan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (02) : 188 - 189
  • [25] PARICALCITOL AND CHOLECALCIFEROL TREATMENT COMPARISON IN STAGE 3-4 CHRONIC KIDNEY DISEASE WITH SECONDARY HYPERPARATHYROIDISM
    Sonikian, Makrouhi
    Giakoumis, Michael
    Pani, Ioanna
    Karaitianou, Aphrodite
    Trovas, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 354 - 355
  • [26] THE EFFECT OF HEMOGLOBIN ON THE RELATIONSHIP BETWEEN GLYCATED HEMOGLOBIN ANDOUTCOMES IN PATIENTS WITH STAGE 3-4 DIABETIC CHRONIC KIDNEY DISEASE
    Kuo, I. Ching
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 194 - 195
  • [27] Systolic Blood Pressure and Outcomes in Stage 3-4 Chronic Kidney Disease Patients: Evidence from a Taiwanese Cohort
    Chiang, Heng-Pin
    Lee, Jia-Jung
    Chiu, Yi-Wen
    Tsai, Jer-Chia
    Hung, Chi-Chih
    Hwang, Shang-Jyh
    Chen, Hung-Chun
    AMERICAN JOURNAL OF HYPERTENSION, 2014, 27 (11) : 1396 - 1407
  • [28] Mineral metabolism and outcomes in chronic kidney disease stage 2–4 patients
    Kamonwan Chartsrisak
    Kotcharat Vipattawat
    Montira Assanatham
    Arkom Nongnuch
    Atiporn Ingsathit
    Somnuek Domrongkitchaiporn
    Vasant Sumethkul
    Sinee Distha-Banchong
    BMC Nephrology, 14
  • [29] Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study
    Hadjiyannakos, Dimitrios
    Filiopoulos, Vassilis
    Trompouki, Sofia
    Sonikian, Makroui
    Karatzas, Ioannis
    Panagiotopoulos, Konstantinos
    Vlassopoulos, Dimosthenis
    CLINICAL KIDNEY JOURNAL, 2013, 6 (02): : 164 - 168
  • [30] Predictors of mortality in patients with chronic kidney disease stages 3-4 without heart disease
    Ostlund, Ylva
    Guron, Gregor
    Saeed, Aso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I942 - I944